Evidence map›Paper›PMID 18957505›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2009

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

David A D'Alessio, Amanda M Denney, Linda M Hermiller, Ronald L Prigeon, Julie M Martin, William G Tharp, Monica Liqueros Saylan, Yanling He, Beth E Dunning, James E Foley and 1 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 3 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. Review
  12. Frontiers in pharmacology · 2024
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

David A D'AlessioUniversity of Cincinnati, Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, ML 0547, Cincinnati, Ohio 45267, USA. dalessd@ucmail.uc.edu
Amanda M Denney
Linda M Hermiller
Ronald L Prigeon
Julie M Martin
William G Tharp
Monica Liqueros Saylan
Yanling He
Beth E Dunning
James E Foley
Richard E Pratley
University of Cincinnati · USUniversity of Vermont · USGeriatric Research Education and Clinical Center · US

Funding

WEIGHT MAINTENANCE AND PSYCHOLOGICAL BENEFITS OF EXERCISEM01RR000109 · NCRR · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI DUMAS, JULIE A · 1985 to 2010
$24.3M
The role of GLP-1 in normal and abnormal glucose toleranceR01DK057900 · NIDDK · UNIVERSITY OF CINCINNATI · PI D'ALESSIO, DAVID A. · 1999 to 2013
$3.4M
NCRR NIH HHS M01 RR000109NCRR NIH HHS M01RR00109NCRR NIH HHS M01RR0808NIDDK NIH HHS DK57900NIDDK NIH HHS R01 DK057900
6 · The paper itself

Abstract

contextDipeptidyl peptidase 4 (DPP-4) inhibitors are proposed to lower blood glucose in type 2 diabetes mellitus (T2DM) by prolonging the activity of the circulating incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1). Consistent with this mechanism of action, DPP-4 inhibitors improve glucose tolerance after meals by increasing insulin and reducing glucagon levels in the plasma. However, DPP-4 inhibitors also reduce fasting blood glucose, an unexpected effect because circulating levels of active GIP and GLP-1 are low in the postabsorptive state.

objectiveThe objective of the study was to examine the effects of DPP-4 inhibition on fasting islet function.

designWe conducted a randomized, double-blind, placebo-controlled trial.

settingThe study was performed in General Clinical Research Centers at two University Hospitals. SUBJECTS: Forty-one subjects with T2DM were treated with metformin or diet, having good glycemic control with glycosylated hemoglobin values of 6.2-7.5%.

interventionSubjects were treated with vildagliptin (50 mg twice daily) or placebo for 3 months, followed by a 2-wk washout. Major Outcome Measure: We measured insulin secretion in response to iv glucose and arginine before and after treatment and after drug washout.

resultsThere were small and comparable reductions in glycosylated hemoglobin in both groups over 3 months. Vildagliptin increased fasting GLP-1 levels in subjects taking metformin, but not those managed with diet, and raised active GIP levels slightly. DPP-4 inhibitor treatment improved the acute insulin and C-peptide responses to glucose (50 and 100% respectively; P < 0.05) and increased the slope of the C-peptide response to glucose (33%; P = 0.023).

conclusionVildagliptin improves islet function in T2DM under fasting conditions. This suggests that DPP-4 inhibition has metabolic benefits in addition to enhancing meal-induced GLP-1 and GIP activity.

Indexed as

AdamantaneAgedDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDouble-Blind MethodFastingGlucagon-Like Peptide 1Glycated HemoglobinHumansIslets of LangerhansMiddle AgedNitrilesPyrrolidinesVildagliptinAdamantaneDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide 1Glycated Hemoglobinhemoglobin A1c protein, humanNitrilesPyrrolidinesVildagliptin

Identifiers

PMID18957505
PMCPMC2630874
OpenAlexW1967477040

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.